Why is albumin administered to improve renal perfusion and support kidney function?

Why Albumin Is Given to Support Kidney Function

Albumin is administered to improve renal perfusion primarily in patients with cirrhosis and specific kidney complications, where it works by expanding central blood volume and enhancing the effects of vasoconstrictor therapy, while also providing anti-inflammatory and endothelial stabilization effects that directly improve renal blood flow autoregulation. 1, 2

Primary Mechanisms of Renal Protection

Volume Expansion and Hemodynamic Effects

• Albumin fills the central circulation, which is critical in cirrhotic patients who have effective arterial hypovolemia despite total body fluid overload 1
• Hyperoncotic albumin (25%) expands plasma volume by 3-4 times the infused volume by drawing fluid from interstitial spaces 3
• This volume expansion enhances splanchnic vasoconstriction when combined with vasoconstrictors like terlipressin, improving renal blood flow 1
• The hemodynamic improvement includes increased mean arterial pressure (+8%), decreased heart rate (-10%), and suppressed plasma renin activity (-67%), all contributing to better renal perfusion 4

Direct Renal Blood Flow Improvement

• Albumin shifts the renal blood flow autoregulation curve toward normalization, resulting in significant increases in renal blood flow 2
• This effect correlates directly with improvement in endothelial activation (r = 0.741, P < 0.001) 2
• The mechanism involves reduction in sympathetic tone, endotoxemia, and oxidative stress, all of which impair renal autoregulation in cirrhosis 2, 5

Evidence-Based Clinical Indications for Kidney Protection

Hepatorenal Syndrome (HRS-AKI)

• Terlipressin plus albumin is the treatment of choice for HRS-AKI, with albumin given at 20-40 g/day 1
• The rationale is to fill central circulation and enhance vasoconstrictor effects, though this is likely achieved after only 1-2 days of albumin administration 1
• Terlipressin plus albumin showed greater improvement in renal function (SCr decreased by 1.1 mg/dL vs 0.6 mg/dL with placebo, P < 0.001) 6
• Continuation beyond 1-2 days should be assessed based on volume status, as prolonged use may not provide additional benefit 1

Spontaneous Bacterial Peritonitis (SBP)

• Albumin reduces kidney impairment by 79% (OR 0.21,95% CI 0.11-0.42) and mortality by 66% (OR 0.34,95% CI 0.19-0.60) in SBP 7
• The landmark trial showed albumin plus antibiotics reduced kidney impairment from 33% to 10% (P = 0.002) and in-hospital mortality from 29% to 10% (P = 0.01) 8
• Dosing: 1.5 g/kg at diagnosis, followed by 1 g/kg on day 3 7, 8
• The mechanism involves both hemodynamic improvement and suppression of inflammatory response 4

Large-Volume Paracentesis

• Albumin prevents paracentesis-induced circulatory dysfunction better than other plasma expanders (RR 1.98 for dysfunction with non-albumin expanders, 95% CI 1.31-2.99) 7
• Standard dosing is 6-8 g per liter of ascitic fluid removed or 20-40 g fixed dose 7
• While mortality benefit is uncertain, albumin prevents the rise in plasma renin activity that predicts renal complications 7

Important Caveats and Contraindications

When Albumin Does NOT Help Kidneys

• Chronic nephrosis: Infused albumin is promptly excreted with no relief of edema or effect on underlying renal lesion 3
• General ICU patients without cirrhosis: No evidence supports albumin for first-line volume replacement or to increase serum albumin levels 7
• Extraperitoneal infections in cirrhosis: No effect on mortality or kidney impairment, but increased pulmonary edema risk (OR 5.17,95% CI 1.62-16.47) 7

Safety Considerations

• Monitor for circulatory overload, especially with hyperoncotic albumin which must be given with or followed by additional fluids in dehydrated patients 3
• In HRS-AKI, albumin is contraindicated when creatinine >5 mg/dL as response rates are very low 1
• Avoid in patients with hypoxemia or ongoing ischemia (coronary, peripheral, mesenteric) when combined with vasoconstrictors 1

Physiological Rationale Beyond Volume

Non-Oncotic Effects

• Albumin attenuates systemic inflammatory responses, though it's uncertain whether effects beyond volume expansion mediate clinical benefit 1
• Provides endothelial stabilization through reduction in endothelial activation markers (von Willebrand factor) 2
• Binds excess bilirubin in acute liver failure, serving dual purpose of oncotic support and toxin binding 3
• Reduces oxidative stress markers (F2α isoprostanes) and neutrophil activation 2

Duration of Effect

• The optimal duration of albumin therapy is 1-2 days for filling central circulation in HRS-AKI 1
• In normally hydrated patients, hemodilution from albumin lasts for a much shorter period than in hypovolemic patients 3
• Point-of-care ultrasonography has been suggested to assess ongoing need, though optimal methods remain unknown 1